Program Description
Fibrosing interstitial lung diseases (F-ILDs) are a heterogeneous and progressive group of pulmonary disorders characterized by irreversible fibrosis, worsening lung function, and a substantial clinical and economic burden. F-ILDs are driven by shared yet variable mechanisms that lead to relentless disease progression, acute exacerbations, and significant comorbidities. Patients with F-ILDs experience high morbidity and mortality, impact on quality of life, and frequent health care resource utilization, including hospitalizations, emergency department visits, and long-term oxygen therapy. Despite advances in disease-modifying treatments, unmet needs remain, particularly in early diagnosis, treatment optimization, and slowing progression across diverse ILD subtypes. New and emerging therapies, along with advances in biomarker development, signal a rapidly evolving treatment landscape. However, delayed diagnosis, undertreatment, and barriers to access including complex prior authorization processes, high out-of-pocket costs, and the need for multidisciplinary care contribute to poor clinical outcomes and escalating direct and indirect costs. Managed care strategies, including value-based frameworks, real-world evidence integration, specialty pharmacy support, and formulary management, play a critical role in improving access and aligning treatment with current evidence. This webinar will provide pharmacists and managed care professionals with the latest clinical data, guideline updates, and practical strategies to address these challenges, optimize treatment selection, and improve outcomes for patients living with F-ILDs.
Target audience: Managed care pharmacist
Type of activity: Application
Release date: September 25, 2026
Expiration date: September 25, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the pathophysiology and clinical burden of fibrosing interstitial lung diseases (F-ILDs), differentiating idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
- Analyze recent clinical data on approved and emerging antifibrotic pharmacologic therapies for F-ILDs to inform clinical decision-making and treatment selection
- Apply current best practices and evolving treatment guidelines to evidence-based management strategies for patients with F-ILDs
- Classify the clinical, financial, and treatment burden of F-ILDs and managed care strategies that facilitate timely access to appropriate interventions
Rachael Prusi, PharmD, MSGH
Director, Specialty Clinical Solutions
Prime Therapeutics
Marquette, MI
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-26-309-H01-P. The activity is available for CE credit through September 25, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Rachael Prusi, PharmD, MSGH, has the following relevant financial relationships with ineligible companies to disclose:
Employee of PBM: Prime Therapeutics, Director of Clinical Solutions
Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Sarah Viruet; and Brianna Winters have no relevant financial relationships with ineligible companies to disclose.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
